Medlab Clinical (ASX: MDC) has partnered with Chronic Pain Australia to develop and provide education for patients and medical professionals in Australia.
Dr Sean Hall, CEO of Medlab said, “we openly welcome this alliance with Chronic Pain Australia, we understand that pain management has to extend beyond opioids, their derivatives, and lifestyle management; new therapies such as NanaBis™ equate to more options, and together we can work on better patient outcomes.”
This approach of partnering with patient advocacy organisations is one way medicinal cannabis companies in Australia working with the strict regulations on marketing and advertising.
As almost all medicinal cannabis products are unregistered medicines, traditional marketing is illegal, making it difficult for companies to increase product uptake and brand recognition.
However, partnering with a patient advocacy group allows companies to have direct access to patients suffering from their target indication – in Medlab’s case, chronic pain.
MGC Pharma has done something similar with Epilepsy Action Australia, where they fund education programs.
